A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With Osteoarthritis
Status:
Completed
Trial end date:
2007-10-09
Target enrollment:
Participant gender:
Summary
This is a double-blind, two-period, placebo controlled cross-over Phase IIa study. This study
is to use CB2 compound of GW842166 in patients with osteoarthritis. The pain assessments and
WOMAC questionnaires will be used in the study after the repeated dose to evaluate the
efficacy of CB2 compound of GW842166.